Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10083576
Filing Date		2002-02-27
First Named Inventor MALE		(AS, Linda H.
Art Unit		1643
Examiner Name HUFF		, Sheela J.
Attorney Docket Number		080371.00005

U.S.PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevant
	1	4376110		1983-03-08	DAVID, Gary S.			
	2	4486530		1984-12-04	DAVID, Gary S.			
	3	4632901		1986-12-30	VALKIRS, Gunars E.			
	4	4727019		1988-02-23	VALKIRS, Gunars E.			
	5	5395754		1995-03-07	LAMBOTTE, Paul P.			
If you wish	n to a	dd additional U.S. Paten	t citatio	n information pl	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevant
	1							
If you wiel	to a	l Id additional LLS Public	had An	nlication citation	n information please click the Ad-	hutton	Add	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10083576
Filing Date		2002-02-27
First Named Inventor MALK		AS, Linda H.
Art Unit		1643
Examiner Name HUFF		, Sheela J.
Attaches Dealest Number		000374 00005

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1							
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	lease click the Add butto	n Add	
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when appropriate, pages(s), volume-is		Ţ5
	1	Wu, et al, J. Cell. Boochem. 54: 32-46 (1994)						
	2	Lasic and Martin, Stealth Liposomes, (1995)						
	3	Hayes, Recent Results Cancer Res., 140: 101-113 (1996)						
	4	Schwartz, et al., Clin. Chem., 39(11B): 2409-2412 (1993)						
	5	Haerslev, et al., Breast Cancer Res. Treat., 37: 101-113 (1996)						
	6	Schmitt, et al., Path. Re	s. Pract., 190: 786	5-791 (19	194)			
	7	Zaccaria, et al., Leukem	ia and Lymphoma	16: 231	-236 (1995)			

	8	Takasaki, et al., J. Nall. Cancer Inst. 73(3): 655-661 (1994)	
	9	Thiele, et al., Hemathologic Path. 7(4): 239-249 (1993)	
10		the transfer of the transfer o	

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Code of USPTO Platert Documents at xee VLSPTO_GOV/ or MPEP 901.04. I Enter of tios that issued the document, by the low-letter gold or WIPO Standard 513.) I "Feel planeses patient counters, the ancidation of the year of the neight of the Emperor many precise its serial running the platent document.

1 Kind of document by the appropriate symbols as andicated on the document under WIPO Standard 51.16 if possible. Spapicant is to place a check mark here if Empirish tanguages translation is stated.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10083576
Filing Date			2002-02-27
First Named Inventor MALK		MALK	(AS, Linda H.
Art Unit			1643
	Examiner Name	HUFF	, Sheela J.
	Attorney Docket Number		080371.00005

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to	make the appro	priate selection(s):
---------------	----------	-------------	----------------	----------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 179(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Joseph L. Morales/	Date (YYYY-MM-DD)	2007-04-12
Name/Print	Joseph L. Morales	Registration Number	58,835

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 231-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.